115 related articles for article (PubMed ID: 24709000)
1. Rationale and efficacy of CD52 targeting in HTLV-1-associated myositis.
Cochereau D; Georgin-Lavialle S; Maisonobe T; Dubourg O; Melboucy-Belkhir S; Hermine O; Aouba A
Joint Bone Spine; 2014 Jul; 81(4):362-5. PubMed ID: 24709000
[TBL] [Abstract][Full Text] [Related]
2. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.
Mone A; Puhalla S; Whitman S; Baiocchi RA; Cruz J; Vukosavljevic T; Banks A; Eisenbeis CF; Byrd JC; Caligiuri MA; Porcu P
Blood; 2005 Nov; 106(10):3380-2. PubMed ID: 16076875
[TBL] [Abstract][Full Text] [Related]
3. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
[TBL] [Abstract][Full Text] [Related]
4. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
5. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
6. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
[TBL] [Abstract][Full Text] [Related]
7. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
Dunleavy K; Wilson WH
Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
[No Abstract] [Full Text] [Related]
8. Alemtuzumab in T-cell malignancies.
Dearden CE; Matutes E; Catovsky D
Med Oncol; 2002; 19 Suppl():S27-32. PubMed ID: 12180489
[TBL] [Abstract][Full Text] [Related]
9. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal anti-CD52 antibodies: a potential mode of therapy for parvovirus B(19) hepatitis.
Granot E; Miskin H; Aker M
Transplant Proc; 2001 May; 33(3):2151-3. PubMed ID: 11377483
[No Abstract] [Full Text] [Related]
11. Human T-cell lymphotropic virus type 1 myositis, peripheral neuropathy, and cerebral white matter lesions in the absence of spastic paraparesis.
Douen AG; Pringle CE; Guberman A
Arch Neurol; 1997 Jul; 54(7):896-900. PubMed ID: 9236579
[TBL] [Abstract][Full Text] [Related]
12. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
Rao SP; Sancho J; Campos-Rivera J; Boutin PM; Severy PB; Weeden T; Shankara S; Roberts BL; Kaplan JM
PLoS One; 2012; 7(6):e39416. PubMed ID: 22761788
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD52 in peripheral T-cell lymphoma.
Piccaluga PP; Agostinelli C; Righi S; Zinzani PL; Pileri SA
Haematologica; 2007 Apr; 92(4):566-7. PubMed ID: 17488672
[TBL] [Abstract][Full Text] [Related]
14. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment.
Owen RG; Hillmen P; Rawstron AC
Clin Lymphoma; 2005 Mar; 5(4):278-81. PubMed ID: 15794865
[TBL] [Abstract][Full Text] [Related]
15. Treatment of refractory acute rejection in a lung transplant recipient with campath 1H.
Reams BD; Davis RD; Curl J; Palmer SM
Transplantation; 2002 Sep; 74(6):903-4. PubMed ID: 12364881
[No Abstract] [Full Text] [Related]
16. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study.
Gorin NC; Isnard F; Garderet L; Ikhlef S; Corm S; Quesnel B; Legrand O; Cachanado M; Rousseau A; Laporte JP
Eur J Haematol; 2013 Oct; 91(4):315-21. PubMed ID: 23738686
[TBL] [Abstract][Full Text] [Related]
17. Humanized Monoclonal Antibody Alemtuzumab Treatment in Transplant.
Bhowmick M; Auckbarallee F; Edgar P; Ray A; Dasgupta S
Exp Clin Transplant; 2016 Feb; 14(1):17-21. PubMed ID: 26862819
[TBL] [Abstract][Full Text] [Related]
18. HTLV-I-associated myelopathy and polymyositis in a US native.
Evans BK; Gore I; Harrell LE; Arnold T; Oh SJ
Neurology; 1989 Dec; 39(12):1572-5. PubMed ID: 2586771
[TBL] [Abstract][Full Text] [Related]
19. T-cell prolymphocytic leukaemia (T-PLL): a rare disease with a grave prognosis.
Vivekanandarajah A; Atallah JP; Gupta S
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645660
[TBL] [Abstract][Full Text] [Related]
20. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.
Clark RA; Watanabe R; Teague JE; Schlapbach C; Tawa MC; Adams N; Dorosario AA; Chaney KS; Cutler CS; Leboeuf NR; Carter JB; Fisher DC; Kupper TS
Sci Transl Med; 2012 Jan; 4(117):117ra7. PubMed ID: 22261031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
